AU2019231321B2 - Combination treatment of chemoresistant cancers - Google Patents

Combination treatment of chemoresistant cancers

Info

Publication number
AU2019231321B2
AU2019231321B2 AU2019231321A AU2019231321A AU2019231321B2 AU 2019231321 B2 AU2019231321 B2 AU 2019231321B2 AU 2019231321 A AU2019231321 A AU 2019231321A AU 2019231321 A AU2019231321 A AU 2019231321A AU 2019231321 B2 AU2019231321 B2 AU 2019231321B2
Authority
AU
Australia
Prior art keywords
ror
antibody
administered
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019231321A
Other languages
English (en)
Other versions
AU2019231321A1 (en
Inventor
Emanuela M. GHIA
Thomas Kipps
Suping Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2019231321A1 publication Critical patent/AU2019231321A1/en
Application granted granted Critical
Publication of AU2019231321B2 publication Critical patent/AU2019231321B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2019231321A 2018-03-09 2019-03-11 Combination treatment of chemoresistant cancers Active AU2019231321B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641035P 2018-03-09 2018-03-09
US62/641,035 2018-03-09
PCT/US2019/021694 WO2019173843A1 (en) 2018-03-09 2019-03-11 Combination treatment of chemoresistant cancers

Publications (2)

Publication Number Publication Date
AU2019231321A1 AU2019231321A1 (en) 2020-10-15
AU2019231321B2 true AU2019231321B2 (en) 2026-01-29

Family

ID=67846369

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019231321A Active AU2019231321B2 (en) 2018-03-09 2019-03-11 Combination treatment of chemoresistant cancers

Country Status (6)

Country Link
US (1) US11883492B2 (https=)
EP (1) EP3762428A4 (https=)
JP (2) JP2021517135A (https=)
CN (1) CN112262157A (https=)
AU (1) AU2019231321B2 (https=)
WO (1) WO2019173843A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250008730A (ko) 2022-03-09 2025-01-15 산유 바이오파마슈티컬스 씨오., 엘티디. Ror1-표적화 결합 분자 및 이의 용도
CN120865418B (zh) * 2025-09-28 2025-12-30 成都微芯新域生物技术有限公司 抗ror1抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
US20180066063A1 (en) * 2012-08-24 2018-03-08 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101807319B1 (ko) * 2008-11-22 2017-12-11 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
WO2011143665A1 (en) * 2010-05-14 2011-11-17 Genentech, Inc. Treatment methods
DK3252076T3 (da) * 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
MX2015007185A (es) * 2012-12-04 2017-09-05 Eisai R&D Man Co Ltd Uso de eribulina en el tratamiento de cancer de pecho.
IL299099B2 (en) * 2016-06-27 2025-07-01 Univ California Cancer treatment combinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180066063A1 (en) * 2012-08-24 2018-03-08 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NCT02776917. "Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer" (05/17/2016) *
ZHANG ET AL.: "Abstract 1193: Treatment of breast cancer xenografts with paclitaxel enriches for cancer stem cells that can be targeted by a ROR1-specific antibody", Cancer Res, 2016. 76(14 Suppl) *
ZHANG, S. ET AL.: "Breast Cancer Initiating Cells Express Functional ROR1, Which Can Be Targeted By Cirmtuzumab To Potentially Mitigate The Risk Of Relapse After Therapy", Cancer Res, 2018. 78(4 Suppl) *
ZHANG, S. ET AL.: "Breast Cancer Initiating Cells Express Functional ROR1, Which Can Be Targeted By Cirmtuzumab To Potentially Mitigate The Risk Of Relapse After Therapy", POSTER IN 2017 SAN ANTONIO BREAST CANCER SYMPOSIUM, 9 December 2017 *

Also Published As

Publication number Publication date
CA3093568A1 (en) 2019-09-12
US11883492B2 (en) 2024-01-30
US20210085786A1 (en) 2021-03-25
AU2019231321A1 (en) 2020-10-15
EP3762428A1 (en) 2021-01-13
WO2019173843A1 (en) 2019-09-12
EP3762428A4 (en) 2021-12-01
JP2021517135A (ja) 2021-07-15
JP2025063134A (ja) 2025-04-15
CN112262157A (zh) 2021-01-22

Similar Documents

Publication Publication Date Title
US20210008206A1 (en) Adenosine pathway inhibitors for cancer treatment
US20230192846A1 (en) Anti-ror-2 antibodies and methods of use
US20240117047A1 (en) Monoclonal antibodies specific for human ror1
JP2025063134A (ja) 化学療法抵抗性がんの組合せ処置
US12576082B2 (en) METTL16 inhibitors and uses thereof
US20240400686A1 (en) Anti-cd3 antibodies and uses thereof
US20210023238A1 (en) Triptolide antibody conjugates
US20250353924A1 (en) Anti-cd84 antibodies and uses thereof
US11739121B2 (en) EPHA2 agonists and uses thereof
US20200261462A1 (en) Combination therapy for cancer treatment
US20240415883A1 (en) Treatment of neuroendocrine cancers
CA3093568C (en) Combination treatment of chemoresistant cancers
US20230127630A1 (en) Igf2bp2 inhibitors and uses thereof
TW202233613A (zh) 去氧胞苷激酶抑制劑之結晶型及其用途
US20250361315A1 (en) Humanized anti-cd84 recombinant protein compositions
US20240317873A1 (en) Anti-hvem antibodies
US20230340089A1 (en) Smc1a antibodies and uses thereof
WO2025235952A1 (en) Humanized anti-cd84 antibodies
HK40046118A (en) Combination treatment of chemoresistant cancers
WO2022055940A1 (en) Vista inhibitors
TW202315894A (zh) 抗受體相關酪胺酸激酶（ｒｙｋ）抗體及其用途